Rossella Rota

Dr. Rossella Rota

Hematology/Oncology Department, Bambino Gesù Children Hospital and IRCCS, Viale San Paolo 15, 00146 Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
BGBerkley E. Gryder
Berkley E. Gryder
MYMarielle E. Yohe
Marielle E. Yohe
HCHsien-Chao Chou
Hsien-Chao Chou
XZXiaohu Zhang
Xiaohu Zhang
JMJoana Marques
Joana Marques
JKJaved Khan
Javed Khan
Alveolar rhabdomyosarcoma is a life-threatening myogenic cancer of children and adolescent young adults, driven primarily by the chimeric transcription factor PAX3–FOXO1. The mechanisms by which PAX3–FOXO1 dysregulates chromatin are unknown. We find PAX3–FOXO1 reprograms the cis-regulatory landscape by inducing de novo super enhancers. PAX3–FOXO1 uses super enhancers to set up autoregulatory loops in collaboration with the master transcription factors MYOG, MYOD, and MYCN. This myogenic super enhancer circuitry is consistent across cell lines and primary tumors. Cells harboring the fusion gene are selectively sensitive to small-molecule inhibition of protein targets induced by, or bound to, PAX3–FOXO1-occupied super enhancers. Furthermore, PAX3–FOXO1 recruits and requires the BET bromodomain protein BRD4 to function at super enhancers, resulting in a complete dependence on BRD4 and a significant susceptibility to BRD inhibition. These results yield insights into the epigenetic functions of PAX3–FOXO1 and reveal a specific vulnerability that can be exploited for precision therapy. Significance: PAX3–FOXO1 drives pediatric fusion-positive rhabdomyosarcoma, and its chromatin-level functions are critical to understanding its oncogenic activity. We find that PAX3–FOXO1 establishes a myoblastic super enhancer landscape and creates a profound subtype-unique dependence on BET bromodomains, the inhibition of which ablates PAX3–FOXO1 function, providing a mechanistic rationale for exploring BET inhibitors for patients bearing PAX-fusion rhabdomyosarcoma. Cancer Discov; 7(8); 884–99. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 783

1 March 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CCCaterina Cenci
Caterina Cenci
RBRita Barzotti
Rita Barzotti
FGFederica Galeano
Federica Galeano
SCSandro Corbelli
Sandro Corbelli
Rossella RotaRossella Rota
Rossella Rota
Angela GalloAngela Gallo
Angela Gallo
Since alterations in post-transcriptional events can contribute to the appearance and/or progression of cancer, we investigated whether RNA editing, catalyzed by the ADAR (adenosine deaminases that act on RNA) enzymes, is altered in pediatric astrocytomas. We find a decrease in ADAR2 editing activity that seems to correlate with the grade of malignancy in children. Despite the loss of ADAR2 editing activity in tumor tissues, the high grade astrocytomas do not exhibit alterations in ADAR2 expression when compared with their specific control tissues. However, high expression levels of ADAR1 and ADAR3 were found in tumors when compared with normal tissues dissected in the same area of the brain. We reintroduced either ADAR2 or the inactive version of ADAR2 in three astrocytoma cell lines (U118, A172, U87). The "reverted" editing status is necessary and sufficient for a significant decrease in cell malignant behavior as measured by proliferation, cell cycle, and migration assays. We show that elevated levels of ADAR1, as found in astrocytomas, do indeed interfere with ADAR2 specific editing activity. Furthermore, we show that the endogenous ADAR1 can form heterodimers with ADAR2 in astrocytes.

29 November 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BGBerkley Gryder
Berkley Gryder
Silvia PomellaSilvia Pomella
Silvia Pomella
CSCarly M. Sayers
Carly M. Sayers
XWXiaoli S. Wu
Xiaoli S. Wu
YSYoung Song
Young Song
JKJaved Khan
Javed Khan

8 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
BGBerkley Gryder
Berkley Gryder
LWLei Wu
Lei Wu
GWGirma M. Woldemichael
Girma M. Woldemichael
Silvia PomellaSilvia Pomella
Silvia Pomella
TQTaylor R. Quinn
Taylor R. Quinn
JKJaved Khan
Javed Khan
Identity determining transcription factors (TFs), or core regulatory (CR) TFs, are governed by cell-type specific super enhancers (SEs). Drugs to selectively inhibit CR circuitry are of high interest for cancer treatment. In alveolar rhabdomyosarcoma, PAX3-FOXO1 activates SEs to induce the expression of other CR TFs, providing a model system for studying cancer cell addiction to CR transcription. Using chemical genetics, the systematic screening of chemical matter for a biological outcome, here we report on a screen for epigenetic chemical probes able to distinguish between SE-driven transcription and constitutive transcription. We find that chemical probes along the acetylation-axis, and not the methylation-axis, selectively disrupt CR transcription. Additionally, we find that histone deacetylases (HDACs) are essential for CR TF transcription. We further dissect the contribution of HDAC isoforms using selective inhibitors, including the newly developed selective HDAC3 inhibitor LW3. We show HDAC1/2/3 are the co-essential isoforms that when co-inhibited halt CR transcription, making CR TF sites hyper-accessible and disrupting chromatin looping.

1 January 2009 in Cell Cycle
Verified
Journal Article
Closed access
RCRoberta Ciarapica
Roberta Ciarapica
GRGiuseppe Russo
Giuseppe Russo
FVFederica Verginelli
Federica Verginelli
LRLavinia Raimondi
Lavinia Raimondi
ADAlberto Donfrancesco
Alberto Donfrancesco
Antonio GiordanoAntonio Giordano
Antonio Giordano
(2009). Deregulated expression of miR-26a and Ezh2 in Rhabdomyosarcoma. Cell Cycle: Vol. 8, No. 1, pp. 172-175. doi: 10.4161/cc.8.1.7292

1 November 2014 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Open access
PDF file
SHSimone Hettmer
Simone Hettmer
ZLZhizhong Li
Zhizhong Li
ABAndrew N. Billin
Andrew N. Billin
FBFrederic G. Barr
Frederic G. Barr
DCD. D. W. Cornelison
D. D. W. Cornelison
CKCharles Keller
Charles Keller
Rhabdomyosarcoma (RMS) represents a rare, heterogeneous group of mesodermal malignancies with skeletal muscle differentiation. One major subgroup of RMS tumors (so-called “fusion-positive” tumors) carries exclusive chromosomal translocations that join the DNA-binding domain of the PAX3 or PAX7 gene to the transactivation domain of the FOXO1 (previously known as FKHR) gene. Fusion-negative RMS represents a heterogeneous spectrum of tumors with frequent RAS pathway activation. Overtly metastatic disease at diagnosis is more frequently found in individuals with fusion-positive than in those with fusion-negative tumors. RMS is the most common pediatric soft-tissue sarcoma, and approximately 60% of all children and adolescents diagnosed with RMS are cured by currently available multimodal therapies. However, a curative outcome is achieved in <30% of high-risk individuals with RMS, including all those diagnosed as adults, those diagnosed with fusion-positive tumors during childhood (including metastatic and nonmetastatic tumors), and those diagnosed with metastatic disease during childhood (including fusion-positive and fusion-negative tumors). This white paper outlines current challenges in RMS research and their implications for developing more effective therapies. Urgent clinical problems include local control, systemic disease, need for improved risk stratification, and characterization of differences in disease course in children and adults. Biological challenges include definition of the cellular functions of PAX-FOXO1 fusion proteins, clarification of disease heterogeneity, elucidation of the cellular origins of RMS, delineation of the tumor microenvironment, and identification of means for rational selection and testing of new combination therapies. To streamline future therapeutic developments, it will be critical to improve access to fresh tumor tissue for research purposes, consider alternative trial designs to optimize early clinical testing of candidate drugs, coalesce advocacy efforts to garner public and industry support, and facilitate collaborative efforts between academia and industry.